SCHEMBL4295121

SCHEMBL4295121

CCOC(=O)c1cccc(-n2nc(C(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 4/20 0.58
MAPK14 Q16539 16/20 0.56
CDK8 P49336 10/20 0.55
MAPK9 P45984 5/20 0.55
PKN2 Q16513 4/20 0.55
JAK3 P52333 3/20 0.55
RET P07949 7/20 0.54
PDGFRA P16234 6/20 0.54
PRKD3 O94806 4/20 0.54
GSK3B P49841 3/20 0.53
MAP4K2 Q12851 3/20 0.53
DYRK3 O43781 1/20 0.53
RPS6KB1 P23443 1/20 0.53
MARK3 P27448 1/20 0.53
FRK P42685 1/20 0.53
STK3 Q13188 1/20 0.53
MAPK13 O15264 2/20 0.53
MAPK12 P53778 2/20 0.53
MAPK11 Q15759 2/20 0.53
PAK4 O96013 4/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4302770 0.90 NTRK1 (0.73) NTRK1MAPK14CDK8MAPK9PKN2
SCHEMBL16317154 0.89 MAPK14 (0.56) NTRK1MAPK14CDK8MAPK9PKN2
SCHEMBL4052780 0.87 NTRK1 (0.60) NTRK1MAPK14CDK8MAPK9PKN2
SCHEMBL4223376 0.87 MAPK14 (0.73) NTRK1MAPK14CDK8MAPK9PKN2
SCHEMBL13576982 0.86 MAPK14 (0.61) NTRK1MAPK14CDK8MAPK9PKN2
SCHEMBL4294709 0.82 MAPK14 (0.62) NTRK1MAPK14CDK8MAPK9PKN2
SCHEMBL4303810 0.81 NTRK1 (0.60) NTRK1MAPK14CDK8MAPK9PKN2
SCHEMBL4048212 0.80 MAPK14 (0.62) NTRK1MAPK14CDK8MAPK9PKN2
SCHEMBL3293873 0.79 MAPK14 (0.74) NTRK1MAPK14CDK8MAPK9PKN2
SCHEMBL3296515 0.79 MAPK14 (0.78) NTRK1MAPK14CDK8MAPK9PKN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090312349-A1 ANTI-INFLAMMATORY MEDICAMENTS DECIPHERA PHARMACEUTICALS, LLC 2009-12-17 US disclosed
US-20090312349-A1 ANTI-INFLAMMATORY MEDICAMENTS DECIPHERA PHARMACEUTICALS, LLC 2009-12-17 US disclosed
US-20070191336-A1 p38 kinase inhibitors DECIPHERA PHARMACEUTICALS, LLC 2007-08-16 US disclosed
US-20070191336-A1 p38 kinase inhibitors DECIPHERA PHARMACEUTICALS, LLC 2007-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312349-A1 ANTI-INFLAMMATORY MEDICAMENTS ABL2, ABL1, PTK2 NTRK1 399/4885MAPK14 80/4885CDK8 949/4885
US-20070191336-A1 p38 kinase inhibitors MAPK1, MAP3K8, MAP3K1 NTRK1 892/4885MAPK14 29/4885CDK8 381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.